Rutul Shah
Direttore/Membro del Consiglio presso Intrexon ActoBiotics NV
Provenienza dei contatti di primo grado di Rutul Shah
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.
15
| Subsidiary | Biotechnology | 15 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Rutul Shah tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Vlaams Instituut voor Biotechnologie - Flanders Institute
 Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | College/University | Chief Executive Officer Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Director of Finance/CFO Director of Finance/CFO | |
| Ghent University | College/University | Graduate Degree Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member Chairman Chairman | |
Q-Biologicals NV
 Q-Biologicals NV BiotechnologyHealth Technology Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Antwerp | College/University | Graduate Degree Graduate Degree | |
| University College Cork | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| Université Catholique de Louvain | College/University | Doctorate Degree Undergraduate Degree | |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Vlerick Leuven Gent Management School | College/University | Masters Business Admin Masters Business Admin | |
| OXURION NV | Pharmaceuticals: Major | Director of Finance/CFO Chairman | |
| BIOTALYS NV | Chemicals: Agricultural | Director/Board Member Director/Board Member | |
| The Janssen Research Foundation | President | ||
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Pharmaceuticals: Major | Chief Executive Officer | |
| Viziphar Biosciences BV | Chief Executive Officer | ||
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Corporate Officer/Principal | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member | |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Chairman | |
| Vivactis NV | Miscellaneous | Director/Board Member | |
EyeD Pharma SA
 EyeD Pharma SA Medical SpecialtiesHealth Technology EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium. | Medical Specialties | Director/Board Member | |
| IMMUNOPRECISE ANTIBODIES LTD. | Biotechnology | Director/Board Member | |
| Fondation Francqui | Director/Board Member | ||
| ORGENESIS INC. | Biotechnology | Director/Board Member | |
Bioxodes SA
 Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Bio-Incubator Leuven
 Bio-Incubator Leuven Real Estate DevelopmentFinance Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe. | Real Estate Development | Director/Board Member | |
| INVENTIVA | Biotechnology | Director/Board Member | |
Fund+
 Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | Investment Managers | Private Equity Investor | |
MaSTherCell SA
 MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | Biotechnology | Director/Board Member | |
Cellaïon SA
 Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
| CoBioRes NV | Director/Board Member | ||
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member | |
Patcobel NV
 Patcobel NV Real Estate DevelopmentFinance Patcobel NV provides real estate services. The private company is based in Kortrijk, Belgium. The CEOs are Cindy van Loock and Patrick Lippens. The Belgian company was founded in 1989. | Real Estate Development | Director/Board Member | |
| Het Vlaams Parlement | Corporate Officer/Principal | ||
| HYLORIS PHARMACEUTICALS SA | Pharmaceuticals: Major | Director/Board Member | |
| Louis Jeantet Foundation | Director/Board Member | ||
DeuterOncology SA
 DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | Biotechnology | Chairman | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree | |
| TIGENIX NV | Medical Specialties | Director/Board Member | |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
| SCYNEXIS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| KIORA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Belgio | 35 |
| Stati Uniti | 8 |
| Svizzera | 4 |
| Francia | 4 |
| Irlanda | 2 |
Settori
| Health Technology | 26 |
| Consumer Services | 9 |
| Finance | 6 |
| Commercial Services | 4 |
| Process Industries | 2 |
Posizioni
| Director/Board Member | 109 |
| Corporate Officer/Principal | 28 |
| Chief Executive Officer | 16 |
| Chairman | 12 |
| Independent Dir/Board Member | 8 |
Contatti più connessi
| Insiders | |
|---|---|
| Chris Buyse | 39 |
| Patrick van Beneden | 32 |
| Mounia Chaoui-Roulleau | 27 |
| Johan Cardoen | 22 |
| Staf van Reet | 22 |
| Jos Sluys | 17 |
| Decebal Bora | 7 |
| Magda van Hijfte | 4 |
| Emil Pot | 4 |
| Lothar Steidler | 4 |
| Sabine Neirynck | 3 |
| Pieter Rottiers | 3 |
| Donald Lehr | 1 |
| Sam Corveleyn | 1 |
| Daan Hommes | 1 |
- Borsa valori
- Insiders
- Rutul Shah
- Connessioni Società
